Dynavax’s Hepatitis B Vaccine Up For FDA Review

Dynavax’s lead compound Heplisav, a vaccine for hepatitis B, will be reviewed by the FDA Vaccines and Related Biological Products Advisory Committee on Nov. 15. Briefing documents for the panel will be released by the FDA by Nov. 13.

Read more>> 

Bloomberg BRIEF Newsletters